Kurt A. Jaeckle

Neurology

4500 San Pablo Rd S
Jacksonville, FL 32224

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 07, 2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas.

Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas.

Journal: bioRxiv : the preprint server for biology

Published: February 12, 2026

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.

Journal: Nature medicine

Published: February 10, 2025

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 15, 2025

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: October 31, 2024

Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas.

Personalized Tumor-Specific Amplified DNA Junctions in Peripheral Blood of Patients with High-Grade Gliomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 27, 2024

Clinical features and outcomes in primary nervous system histiocytic neoplasms.

Clinical features and outcomes in primary nervous system histiocytic neoplasms.

Journal: Blood cancer journal

Published: April 21, 2024

Case Report: "Aggressive" perioperative antiseizure medication prophylaxis in patients with glioma-related epilepsy at high risk of early postoperative seizures following awake craniotomy.

Case Report: "Aggressive" perioperative antiseizure medication prophylaxis in patients with glioma-related epilepsy at high risk of early postoperative seizures following awake craniotomy.

Journal: Frontiers in surgery

Published: August 23, 2023

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 26, 2022

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).

Journal: Neuro-oncology advances

Published: June 06, 2022

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.

Journal: Neuro-oncology

Published: February 14, 2022

Showing 1-12 of 47

Last Updated: 09/26/2026